NMIBC Drug Pipeline: Immunotherapy & Gene Therapy — PatSnap Eureka
Non-Muscle Invasive Bladder Cancer: Intravesical Immunotherapy, Gene Therapy & Targeted Approaches
NMIBC represents 70–80% of all new bladder cancer diagnoses. With BCG failure affecting up to 40% of patients, a new wave of intravesical immunotherapy, oncolytic virotherapy, ADC delivery, and FGFR-targeted agents is reshaping the pipeline. Explore the patent intelligence behind it.
The Unmet Need Driving NMIBC Pipeline Innovation
Non-muscle invasive bladder cancer (NMIBC) encompasses three pathological substages: pTa (non-invasive papillary urothelial carcinoma), pT1 (lamina propria invasion), and pTis (carcinoma in situ, CIS). Intravesical BCG immunotherapy remains the standard adjuvant after TURBT for high-risk NMIBC, yet up to 40% of patients experience BCG failure — creating a well-defined and commercially significant unmet need that motivates most pipeline innovation.
The field is at an inflection point, driven by BCG shortages, a substantial BCG-unresponsive or BCG-refractory patient population, and a near-absence of approved second-line intravesical options. This has accelerated innovation across immune checkpoint modulation, oncolytic virotherapy, ADC-based intravesical delivery, FGFR-targeted small molecules, and mycobacterial immunotherapeutics.
The PD-L1/PD-1 axis is the single most represented target across the patent dataset, addressed by MedImmune, Genentech/Roche, AstraZeneca, and Foundation Medicine. PD-L1 is reported to be expressed in 12% of bladder tumor cells and up to 50% of malignant urothelial cells within carcinoma in situ. Other key targets include Nectin-4 (191P4D12), EpCAM, FGFR3, CDCP1, LAG3/TIGIT, and long non-coding RNA (lncRNA) for genomic subtyping. Explore the full target landscape with PatSnap IP analytics.
NMIBC Pipeline: Patent Activity by Modality & Assignee
Patent filing patterns reveal where commercial and clinical investment is concentrated across the NMIBC therapeutic landscape.
Patent Filings by Therapeutic Modality
TARIS Biomedical and Agensys lead with 8+ filings each; CG Oncology's 2025 filings signal active clinical-stage activity
Jurisdictional Coverage by Top NMIBC Assignees
Global patent coverage signals commercial intent; TARIS and Agensys hold the broadest multi-jurisdictional portfolios
Eight Innovation Tracks in the NMIBC Drug Pipeline
Patent and literature signals across intravesical immunotherapy, oncolytic virotherapy, ADCs, FGFR inhibitors, multispecific antibodies, and genomic subtyping strategies.
Intravesical BCG & Next-Generation Mycobacterial Immunotherapy
Standard intravesical BCG remains the reference background for virtually all NMIBC innovation. Serum Life Science Europe GmbH (Canada, 2023) has filed a patent disclosing a recombinant Mycobacterium cell engineered for use specifically in second-line NMIBC therapy following BCG failure, positioning it as a clinically actionable successor to standard BCG.
Patent-only · Early translational stageIntravesical Oncolytic Virotherapy (CG Oncology & Istari)
CG Oncology, Inc. (WO, 2025) discloses intravesical administration of cretostimogene grenadenorepvec (an oncolytic adenovirus) for NMIBC, alone or combined with immune checkpoint modulators or chemotherapy. Istari Oncology (WO, 2023) adds a mechanistically distinct chimeric poliovirus (Sabin type I/HRV2 IRES) in a structured induction + maintenance regimen. Priority applications from 2022–2025 suggest IND-enabling or early clinical stages.
WO 2025 filings · Active clinical program signalsADC-Based Intravesical Therapy (Nectin-4 / EpCAM / HER2)
Agensys, Inc. holds an extensive multi-jurisdictional family (WO, US, CA, TW, JP, CN, AU) covering intravesical anti-Nectin-4 ADC (191P4D12) for BCG-unresponsive NMIBC. Viventia Biosciences (CN) discloses EpCAM-targeted immunoconjugates with induction and maintenance dosing. This represents a conceptually novel direction: applying ADC technology via intravesical instillation to achieve local cytotoxicity while potentially limiting systemic exposure. Learn more about ADC pipeline intelligence.
Multi-jurisdictional · BCG-unresponsive populationFGFR Tyrosine Kinase Inhibitors (Janssen Pharmaceutica)
Janssen Pharmaceutica NV (WO/IL, 2021–2022) holds the most NMIBC-specific targeted therapy filings for FGFR inhibition in HR-NMIBC and IR-NMIBC. FGFR3 is identified as a driver mutation in a significant fraction of NMIBC tumors. A complementary patent from Institut François Radvanyi (US, 2013) addresses CDKN2A as a predictive biomarker in FGFR3-mutant NMIBC, defining a precision oncology subpopulation. Track FGFR patent activity via PatSnap analytics.
HR-NMIBC & IR-NMIBC specific · CDKN2A co-mutation markerContinuous Intravesical Gemcitabine Delivery (TARIS Biomedical)
TARIS Biomedical LLC is the most prolific single assignee in this dataset with at least 8 distinct filings spanning SG, IL, AU, JP, and WO jurisdictions. Their sustained-release intravesical device delivers continuous gemcitabine for BCG-refractory and BCG-naive HR-NMIBC. The most recent WO 2026 filing (priority from September–October 2024 provisionals) indicates a clinical dataset likely supports specific BCG-naive HR-NMIBC claims.
8+ filings · WO 2026 most recent · Clinical-stage signalsCD3 × EpCAM Multispecific Antibodies (Horst Lindhofer)
Horst Lindhofer holds a family of patents (WO, CA, AU, JP) for CD3 × EpCAM bispecific antibodies administered intravesically for NMIBC and other urinary tract neoplasms. The mechanism relies on T-cell redirection to EpCAM-expressing urothelial tumor cells within the bladder lumen. Retrieved Japanese patent text explicitly states PD-L1 is expressed in up to 50% of malignant urothelial cells and situates BCG as the main current option, highlighting the therapeutic gap being addressed.
Active legal status multiple jurisdictions · Commercial intentIntravesical PD-1/PD-L1 Checkpoint Blockade (Photocure ASA)
Photocure ASA has filed Chinese patents describing intravesical instillation of anti-PD-L1 and/or anti-PD-1 antibodies as neoadjuvant therapy for high-risk NMIBC patients scheduled for cystectomy, including patients with multiply recurrent high-grade tumors or CIS. This is mechanistically distinct from systemic checkpoint inhibition and specifically addresses the intravesical delivery route for immune checkpoint blockade. NIH clinical trial databases provide complementary clinical context.
CN 2018 patent · Active status · Preclinical–translationalIL-2 Fusion Protein–Based Immunotherapy (Altor BioScience)
Altor BioScience Corporation discloses IL-2 fusion protein combinations with one or more therapeutic agents for bladder cancer treatment (US, 2015; AU, 2018). Retrieved text specifically notes that bladder cancer has been well-characterized at the molecular level but has a historical paucity of successful clinical trials with molecular targeted agents, providing rationale for cytokine-based immunotherapy as an alternative approach.
US & AU patents · Development stage not explicitly statedConvergent Combination Strategies in NMIBC
Patent signals reveal several convergent strategies combining intravesical immunostimulation with systemic or locoregional checkpoint modulation.
Oncolytic Virus + Immune Checkpoint Modulator
Both CG Oncology WO 2025 filings explicitly claim combinations of intravesical cretostimogene grenadenorepvec with immune checkpoint modulators or chemotherapy. The Cold Genesys JP patent (2019) describes a Phase I/II study combining intravesical CG0070 with intravesical CTLA-4 inhibition and systemic OX40 agonist, measuring PD-L1/PD-1 changes as primary efficacy endpoints. Intravesical immunostimulation + checkpoint modulation is an emerging paradigm.
Intravesical Gemcitabine + Immunomodulating Agent
Multiple TARIS Biomedical filings (SG 2018, IL 2022, AU 2023) claim co-administration of gemcitabine with an immunomodulating agent for lower tract urothelial carcinoma. Retrieved JP text from TARIS explicitly notes that local gemcitabine can modulate the tumor microenvironment immune response, induce systemic immunity, and trigger antigen presentation — providing mechanistic rationale for this combination approach.
PD-1 × LAG3 Bispecific + Anti-TIGIT (Roche WO 2024)
The Roche WO 2024 filing is the most recent multi-checkpoint combination patent in this dataset, combining a PD-1/LAG3 bispecific antibody with an anti-TIGIT antagonist antibody for urothelial bladder cancer treatment. This signals movement toward dual or triple checkpoint co-inhibition beyond standard PD-1/PD-L1 monotherapy, with LAG3 and TIGIT as the next-generation co-inhibitory targets.
Biomarker-Guided Oncolytic Therapy (CG Oncology 2025)
The CG Oncology biomarker-guided WO 2025 patent explicitly incorporates predictive biomarker selection into oncolytic virus therapy protocols, signaling convergence of companion diagnostics with intravesical immunotherapy. The AstraZeneca patent also introduces blood-based mutational burden and circulating tumor DNA (ctDNA) mutations as biomarkers for sensitivity to durvalumab, extending biomarker-guided selection to NMIBC contexts.
Key Organizations in the NMIBC Patent Dataset
Patent activity strongly dominates over academic literature. Innovation is primarily commercial and IP-driven, with university contributions focused on subtyping and biomarker identification.
| Assignee | Modality Focus | Jurisdictions | Filing Recency | Stage Signal |
|---|---|---|---|---|
| TARIS Biomedical LLC | Intravesical Gemcitabine | SG, IL, AU, JP, WO | WO 2026 (most recent) | Clinical-stage |
| Agensys, Inc. (Astellas) | Nectin-4 ADC | WO, US, CA, TW, JP, CN, AU | US 2025 (pending) | Active clinical dev. |
| Horst Lindhofer | CD3×EpCAM Bispecific | WO, CA, AU, JP | JP 2023 | Active IP protection |
| MedImmune / AstraZeneca | Anti-PD-L1 (durvalumab) | SG, IL | Multiple active | Clinical-stage |
| Genentech / F. Hoffmann-La Roche | Atezolizumab / PD-1×LAG3 | JP, MX, CN, WO | WO 2024 | Clinical-stage |
| Janssen Pharmaceutica NV | FGFR Inhibitors | WO, IL | 2021–2022 | Translational/clinical |
| CG Oncology, Inc. | Oncolytic Adenovirus | WO | WO 2025 (most recent) | Clinical readout signal |
| Istari Oncology, Inc. | Chimeric Poliovirus | WO | WO 2023 | IND-enabling stage |
Track Every NMIBC Assignee's Filing Activity
Monitor new patents, jurisdictional expansions, and competitive moves across the full NMIBC landscape with PatSnap Eureka.
Clinical Evidence Embedded in NMIBC Patent Filings
Multiple Agensys NMIBC filings (WO 2023, US 2025) explicitly identify BCG-unresponsive disease as a defined clinical subpopulation, suggesting alignment with FDA regulatory guidance frameworks. Retrieved filings describe radical cystectomy as the remaining option for BCG-non-responders, motivating bladder-preserving intravesical ADC development.
The Agensys MIBC ADC WO 2023 filing cites the ABACUS Phase II study (Powles et al., 2018), reporting 29% pathological complete response (pCR) with neoadjuvant atezolizumab in cisplatin-ineligible MIBC patients, with pCR rising to 40% in PD-L1-positive patients. Genentech/Roche JP patents (2023) reference the IMvigor011 Phase III double-blind randomized trial of adjuvant atezolizumab vs. placebo in ctDNA-positive high-risk MIBC post-cystectomy.
Kyushu University (EP 2022, US 2022) has filed patents for SNP-based prediction of BCG intravesical therapy resistance and relapse, representing translational tools to prospectively identify BCG-refractory patients before treatment. The European Patent Office EP filing confirms international translational intent. Track biomarker patent development via PatSnap analytics.
The TARIS Biomedical WO 2026 filing claims priority from provisional applications filed in September and October 2024, indicating a clinical dataset is likely supporting specific claims about BCG-naive HR-NMIBC. CG Oncology WO 2025 filings claim priority from provisional applications filed in May 2024 and April 2025, consistent with an active clinical program generating data at the time of filing.
NMIBC Drug Pipeline — Key Questions Answered
Non-muscle invasive bladder cancer (NMIBC) accounts for approximately 70–80% of all newly diagnosed bladder cancer cases. Among NMIBC substages, papillary disease (Ta) accounts for approximately 70% of NMIBC cases, T1 disease for ~20%, and CIS for ~10%.
Up to 40% of NMIBC patients experience BCG failure, creating a well-defined and commercially significant unmet need that motivates most of the innovation in the NMIBC drug pipeline.
The most frequently cited therapeutic target across the NMIBC patent dataset is the PD-L1/PD-1 axis, addressed by MedImmune, Genentech/Roche, AstraZeneca, and Foundation Medicine. Other key targets include Nectin-4 (191P4D12), EpCAM, FGFR3, CDCP1, LAG3/TIGIT, and long non-coding RNA (lncRNA) for subtyping.
CG Oncology, Inc. has filed two WO 2025 patents disclosing intravesical administration of cretostimogene grenadenorepvec (an oncolytic adenovirus) for NMIBC, either alone or combined with immune checkpoint modulators or chemotherapy. Istari Oncology, Inc. (WO, 2023) discloses intravesical instillation of a chimeric poliovirus (Sabin type I/HRV2 IRES) in a structured induction and maintenance regimen for NMIBC.
FGFR3 is a frequently mutated receptor tyrosine kinase in NMIBC. Janssen Pharmaceutica NV patents specifically address FGFR inhibition in high-risk (HR-NMIBC) and intermediate-risk (IR-NMIBC) disease. CDKN2A loss-of-function mutations co-occurring with activating FGFR3 mutations are described as a prognostic marker in NMIBC, defining a subpopulation for precision oncology selection.
Agensys, Inc. has filed an extensive multi-jurisdictional patent family covering intravesical ADC treatment of NMIBC using an anti-Nectin-4 ADC targeting the 191P4D12 protein. The intravesical delivery route is explicitly claimed for NMIBC, distinguishing this from systemic ADC approaches used in MIBC. This represents a conceptually novel direction: applying ADC technology via intravesical instillation to achieve local cytotoxicity against Nectin-4-expressing urothelial cells while potentially limiting systemic exposure.
Still have questions about the NMIBC pipeline? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About NMIBC PatentsAccelerate Your NMIBC Drug Discovery & IP Strategy
Join 18,000+ innovators already using PatSnap Eureka to track the NMIBC pipeline, identify BCG-failure unmet needs, and monitor competitive patent activity across intravesical immunotherapy, ADCs, and targeted therapies.
References
- Recombinant Mycobacterium as an Immunotherapeutic Agent for the Second-Line Therapy of Bladder Carcinoma — Serum Life Science Europe GmbH, CA 2023
- Methods of Treating Bladder Cancer Using an Oncolytic Virus — CG Oncology, Inc., WO 2025
- Methods and Compositions for Biomarker-Guided Bladder Cancer Therapy — CG Oncology, Inc., WO 2025
- Methods for Treating Bladder Cancers by Intravesical Instillation of a Chimeric Poliovirus — Istari Oncology, Inc., WO 2023
- Methods for Treating NMIBC with ADC that Bind to 191P4D12 Proteins — Agensys, Inc., WO 2023
- Methods for Treating NMIBC with ADC that Bind to 191P4D12 Proteins — Agensys, Inc., US 2025
- Methods for Treating EpCAM-Positive Bladder Cancer — Viventia Biosciences Inc., CN 2018
- FGFR Tyrosine Kinase Inhibitors for the Treatment of High-Risk NMIBC — Janssen Pharmaceutica NV, IL 2022
- CDKN2A as a Prognostic Marker in Bladder Cancer — Radvanyi, François, US 2013
- Methods of Treating High-Risk NMIBC Unresponsive to BCG Therapy — TARIS Biomedical LLC, WO 2025
- Intravesical Gemcitabine for Use in Treating BCG-Naive HR-NMIBC — TARIS Biomedical LLC, WO 2026
- Multispecific Antibodies for Use in the Treatment of a Neoplasm of the Urinary Tract — Lindhofer, Horst, WO 2017
- Intravesical Treatment for Bladder Cancer — Photocure ASA, CN 2018
- Methods for Treating Neoplasia (IL-2 Fusion Protein) — Altor BioScience Corporation, US 2015
- Treatment of Bladder Cancer with Radiolabeled Antibodies Targeting CDCP1 — The Regents of the University of California, US 2024
- Methods and Compositions for Treating Urothelial Bladder Cancer — F. Hoffmann-La Roche AG, WO 2024
- Biomarker for Predicting Therapeutic Effects of BCG Intravesical Therapy — Kyushu University, US 2022
- Methods of Treating Solid or Lymphoid Tumors with Combination Therapy — Cold Genesys, Inc., JP 2019
- World Health Organization — Cancer Classification and Bladder Cancer Epidemiology
- National Institutes of Health — Bladder Cancer Clinical Trial Registry
- U.S. Food and Drug Administration — BCG-Unresponsive NMIBC Regulatory Guidance
- European Patent Office — NMIBC Patent Database
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.